Compositions and methods for treating type 1 and type 2 diabetes and related disorders
AssigneeThe Salk Institute for Biological Studies
InventorsRonald M. Evans, Eiji Yoshihara, Michael R. Downes, Ruth T. Yu, Annette R. Atkins
Life of this patent
Estimating the term…
Abstract
The invention features compositions comprising in vitro generated beta cells capable of glucose-stimulated insulin secretion, methods of inducing beta cell maturation from embryonic or induced pluripotent stem cell-derived beta-like cells, and methods of using in vitro generated beta cells for the treatment of type 1 diabetes, type 2 diabetes, or a related disorder.
Claims20
A method of treating and/or ameliorating type 1 or type 2 diabetes in a mammalian subject having or suspected of having type 1 or type 2 diabetes, the method comprising:
- administering to the mammalian subject an effective amount of glucose-responsive mammalian adipose derived β-like cells, which overexpress recombinant estrogen-related receptor gamma (ERRγ) and pancreatic and duodenal homeobox 1 (PDX1);
- and
- reducing or normalizing blood glucose levels in the subject following administration of the glucose-responsive mammalian adipose derived β-like cells, thereby treating and/or ameliorating type 1 or type 2 diabetes in the subject.
A method of reducing elevated blood glucose levels in a mammalian subject in need thereof, the method comprising:
- administering to the mammalian subject an effective amount of glucose-responsive, mammalian adipose derived β-like cells, which overexpress recombinant ERRγ and pancreatic and duodenal homeobox 1 (PDX1);
- thereby reducing elevated blood glucose levels in the subject.
A method of treating and/or ameliorating type 1 or type 2 diabetes in a mammalian subject having or suspected of having type 1 or type 2 diabetes;
- treating and/or ameliorating hyperglycemia in a mammalian subject having or suspected of having hyperglycemia;
- and/or reducing elevated blood glucose levels in a mammalian subject in need thereof;
- the method comprising:
- administering to the mammalian subject an effective amount of glucose-responsive human adipose derived β-cells that have been differentiated from human adipose-derived progenitor cells to glucose-responsive adipose-derived β-cells by overexpressing in the human adipose-derived progenitor cells recombinant estrogen-related receptor γ (ERRγ) and pancreatic and duodenal homeobox 1 (PDX1);
- wherein the overexpression of ERRγ and PDX1 differentiates the adipose-derived progenitor cells into glucose-responsive β-cells which are capable of glucose-stimulated insulin secretion;
- and
- treating and/or ameliorating type 1 or type 2 diabetes in the mammalian subject;
- treating or ameliorating hyperglycemia in the mammalian subject;
- and/or reducing elevated blood glucose levels in the mammalian subject following administration of the glucose-responsive human adipose derived B-cells.
Dependencies are inferred from the claim text.